Sintilimab
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cancer of Unknown Primary Site
Conditions
Cancer of Unknown Primary Site
Trial Timeline
Aug 26, 2021 → Apr 3, 2025
NCT ID
NCT05024968About Sintilimab
Sintilimab is a phase 2 stage product being developed by Innovent Biologics for Cancer of Unknown Primary Site. The current trial status is completed. This product is registered under clinical trial identifier NCT05024968. Target conditions include Cancer of Unknown Primary Site.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05594381 | Phase 2 | UNKNOWN |
| NCT05024968 | Phase 2 | Completed |
| NCT04400851 | Phase 1 | UNKNOWN |
| NCT04220944 | Phase 1 | Active |
| NCT03812549 | Phase 1 | Completed |
| NCT03228836 | Phase 2 | Completed |
Competing Products
20 competing products in Cancer of Unknown Primary Site
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E7389 | Eisai | Phase 1 | 33 |
| Veliparib | AbbVie | Phase 2 | 52 |
| AK-105 | Akeso | Phase 1 | 32 |
| XL820 | Exelixis | Phase 1 | 30 |
| Lymphoseek | Navidea Biopharmaceuticals | Phase 3 | 69 |
| Lymphoseek | Navidea Biopharmaceuticals | Phase 3 | 69 |
| ALT-P7 (HM2-MMAE) | Alteogen | Phase 1 | 33 |
| pegylated liposomal doxorubicin (PLD) + PD-1 | CSPC Pharmaceutical Group Limited | Phase 2 | 51 |
| Biomarkers blood, urine and microbiota samples | Eli Lilly | Pre-clinical | 23 |
| gemcitabine + paclitaxel + bevacizumab | Eli Lilly | Phase 2 | 52 |
| pemetrexed | Eli Lilly | Phase 2 | 52 |
| LY3300054 + Prexasertib | Eli Lilly | Phase 1 | 33 |
| BBP-398 with nivolumab | BridgeBio Pharma | Phase 1 | 30 |
| Cetuximab + Oxaliplatin + Capecitabine | Eli Lilly | Phase 2 | 52 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 52 |
| Gemcitabine + Adriamycine + Paclitaxel | Eli Lilly | Phase 2 | 52 |
| Selpercatinib | Eli Lilly | Pre-clinical | 23 |
| Pemetrexed + Cisplatin + Placebo + Pemetrexed | Eli Lilly | Phase 3 | 77 |
| NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRT | Nanobiotix | Phase 1/2 | 36 |
| NBTXR3 | Nanobiotix | Phase 1/2 | 36 |